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ABSTRACT   
Tuberculosis (TB) and leprosy are mycobacterial diseases that still represent significant public 
health challenges. Bacille Calmette–Guérin (BCG), the only available TB and Leprosy vaccine 
use as Immunoprophylaxis and has already given in infants. However, the evidence of TB and 
Leprosy infection in Indonesia remain high. In the last 10 years, chemoprophylaxis for both 
TB and leprosy were extensively done. However the effectiveness between immunoprophylaxis 
and chemoprophylaxis remains unclear. 
 
ABSTRAK  
Tuberkulosis (TB) dan kusta merupakan penyakit mycobacterium yang masih masih menjadi 
tantangan kesehatan di masyarakat. Bacille Calmette-Guérin (BCG), satu-satunya vaksin yang 
tersedia untuk mencegah TB dan kusta yang tersedia, digunakan sebagai imunoprofilaksis dan 
telah diberikan pada bayi lebih dari 30 tahun. Namun, infeksi TB dan Kusta di Indonesia masih 
tetap tinggi. Dalam 10 tahun terakhir, kemoprofilaksis untuk TB dan kusta dilakukan secara 
luas. Efektivitas antara imunoprofilaksis dan kemoprofilaksis masih belum jelas. 
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INTRODUCTION  
 Tuberculosis (TB) and leprosy are 
both airborne infections and Neglected 
Tropical Diseases (NTD) caused by 
Mycobacteria spp (1,2).  
Tuberculosis (TB) is caused by 
Mycobacterium tuberculosis, slow growing 
bacteria that has high affinity to human 
macrophage, especially lung’s macrophage 
(3). Meanwhile, Leprosy and also known as 
Hansen’s disease or Kusta is a NTD caused 
by Mycobacterium leprae. It can affect the 
nerves, skin, eyes, and lining of the nose 
(nasal mucosa) (1).  
By an early detection and proper 
treatment, both of TB and leprosy can be 
cured, continue to work and lead an active 
life during and after treatment (2,4,5). 
Tuberculosis (TB) and leprosy do not 
spread easily, however, once those neglect 
and untreated could cost more.  When 
leprosy is left untreated, the nerve damage 
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can result in crippling of hands and feet, 
paralysis, and blindness. Leprosy is a 
disease that predominantly affects the skin 
and peripheral nerves, resulting in 
neuropathy and associated long-term 
consequences, including deformities and 
disabilities (6), also with TB, it can cause 
respiratory failure and end up with death 
(2). However, the transmission numbers of 
TB and leprosy remain high. In 2016, 
Indonesia was in the 3rd place for leprosy 
new cases, after India and Brazil, and 5th 
place for TB new cases(7). 
Moreover, both of TB and leprosy 
still had big stigma issue in the community 
thus people whom affected with TB and 
leprosy, mostly were hide their symptoms 
and refused the treatment. Transmission of 
TB and leprosy could stop by treating the 
patients or index cases, and giving the 
contacts with immunoprophylaxis and 
chemoprophylaxis(3,8–10).  
In order to support stop 
transmission of TB and leprosy, in 2016, 
the WHO launched the Global Leprosy 
Strategy 2016-2020 "accelerate world zero 
leprosies" (6). 
Immunoprophylaxis versus 
Chemoprophylaxis as prevention in 
Tuberculosis and Leprosy 
Basic interventions for TB and 
leprosy control strategy are the provision of 
multidrug therapy (MDT) (12–14). 
Prevention in TB and Leprosy now are 
common to stop transmission of the 
infection. Both immunoprophylaxis and 
chemoprophylaxis or combines are the 
prevention strategies (3,9,15). 
Immunoprophylaxis is a 
protection against infectious disease by 
immunizations acquired by individuals 
either passively or actively. 
Immunoprophylaxis effectively to 
prevention of infectious diseases. Both 
poverty-related mycobacterial diseases 
require better tools to improve disease 
control. For leprosy, there has been an 
increased emphasis on developing tools for 
improved detection of infection and early 
diagnosis of disease (16). For TB, there has 
been a similar emphasis on such diagnostic 
tests, while increased research efforts have 
also focused on the development of new 
vaccines (15). Bacille Calmette–Guérin 
(BCG), the only available TB vaccine, 
provides insufficient and inconsistent 
protection to pulmonary TB in adults. The 
impact of BCG on leprosy, however, is 
significant, and the introduction of new TB 
vaccines that might replace BCG could, 
therefore, have serious impact also on 
leprosy. Given the similarities in antigenic 
makeup between the pathogens 
Mycobacterium tuberculosis (Mtb) and M. 
leprae, it is well possible, however, that 
new TB vaccines could cross-protect 
against leprosy(15).  Immunoprophylaxis 
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on tuberculosis and Mycobacterium leprae 
to date the BCG vaccine. The protective 
effect of BCG varied 2-83% to prevent 
pulmonary tuberculosis and 58-74% in 
preventing extra pulmonary TB. While the 
efficacy of leprosy is only around 26-41% 
in experimental studies about 61% in the 
observational studies, with a mild 
difference between the types of 
paucibacillary leprosy (62%) and 
multibacillary (76%) (17). 
Immunotherapy has a dual role in 
the treatment of tuberculosis is increasing 
the success rate for the treatment of TB-
MDR; shorten treatment for tuberculosis; 
and increasing immunity of individuals 
who have been treated with drug therapy, 
thereby preventing recurrent disease (either 
through relapse or reinfection). In patients 
with tuberculosis, immunotherapy aims to 
"reactivate" or enhance the immune 
response either by promoting protective 
(Th1) immunity or immune system by 
blocking the harmful response (Th2). 
Improving the Th1 response can lead to the 
release of Th1 cytokines related systemic 
necrosis lesions of tuberculosis (Koch 
phenomenon) (11). 
New TB subunit vaccines currently 
evaluated in human phase I and II studies 
indeed often contain antigens with 
homologs in M. leprae. In this review, we 
discuss pre-clinical studies and clinical 
trials of subunit or whole mycobacterial 
vaccines for TB and leprosy and reflect on 
the development of vaccines that could 
provide protection against both diseases. 
Furthermore, we provide the first 
preclinical evidence of such cross-
protection by Mtb antigen 85B (Ag85B)-
early secretory antigenic target (ESAT6) 
fusion recombinant proteins in in vivo 
mouse models of Mtb and M. leprae 
infection. We propose that preclinical 
integration and harmonization of TB and 
leprosy research should be considered and 
included in global strategies with respect to 
cross-protective vaccine research and 
development.  
Chemoprophylaxis is the 
administration of the drug to prevent the 
development of a disease. The use of 
chemo-prophylactic agents is based on 
knowledge of the epidemiology and clinical 
implications of the infectious diseases from 
which protection is sought. Generally, 
chemoprophylaxis is taken for diseases that 
are common, or where the clinical impact of 
infection is high like tuberculosis and 
leprosy. Tuberculosis and leprosy are a 
diseases with high transmission rates, those 
increasing the risk of transmission to people 
in close contact with patients. Therefore it 
takes prevention by given 
chemoprophylaxis for prevention (6). In 
granting chemoprophylaxis as prevention 
of leprosy, in 1960-1970, giving dapsone as 
chemoprophylaxis leprosy. In 1988 began 
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at the tested use of rifampicin as 
chemoprophylaxis, due to noticeable 
decrease in cases of leprosy, then in 1990 
combination of rifampicin ofloxacin-
minocycline (ROM) given as prevention on 
adults and in children aged <15 years and in 
2000 single doses of rifampicin (SDR) 
tested in 5 islands in Indonesia as 
chemoprophylaxis leprosy (18), In 1991 the 
multi-drug therapy (MDT), that three anti-
bacterial drugs (rifampicin, dapsone, and 
clofazimine) provide a more effective, 
where MDT is reducing the number of 
leprosy patients treated from 5.3 million in 
1985 to 3, 1 million in 1991. This decline of 
the prevalence gives hope to the world to 
achieve the target elimination of leprosy in 
2000 (19). 
This time by providing the use of 
single doses of rifampicin (SDR) as a 
preventive treatment for adults and children 
(2 years and above) in contact with the 
patients, by ensuring there is no TBC as 
contraindications and make sure no other 
contraindications. This intervention is 
carried out with the following 
requirements: (i) adequate management of 
contacts, and (ii) there is informed consent 
given chemoprophylaxis for the prevention 
of leprosy (19). The results showed that if 
the third intervention (detection and 
treatment of subclinical infection, 
chemoprophylaxis, and BCG), when 
applied consistently to individual contacts 
of leprosy patients, will reduce the 
incidence of disease in populations (18). 
Based on the research results of the 
main benefits of prophylaxis SDR gave to 
leprosy patient’s contact or as post-
exposure prophylaxis (PEP), which can 
reduce the risk of leprosy by 60%. Given of 
the SDR in leprosy contacts associated with 
a 57% reduction in the risk of leprosy after 
2 years and 30% after 5-6 years, with that 
none of TBC infection in individuals 
because SDR in individuals who showed 
symptoms of active tuberculosis, can 
caused the risk of resistance in tuberculosis 
to be MDR-TB (20). The risk of leprosy 
infected for individuals who live together 
and close contact with patients 
multibacillary (MB) is 5-10 times higher, 
and 2-3 times higher in patients with 
paucibacillary (PB), compared to people 
who are not close contacts (5). The result in 
combining BCG and rifampicin for leprosy 
was also shown no different compare to 
SDR. 
A study testing the effectiveness of 
the SDR as chemoprophylaxis leprosy 
(COLEP) in Bangladesh. The result is the 
effectiveness of chemoprophylaxis SDR as 
leprosy (COLEP) is SDR does not have 
significant protection against the 
development of leprosy on contact. 
Furthermore, SDR does not protect against 
the development of multibacillary leprosy 
(MB), but protects against the development 
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of paucibacillary leprosy (PB) and single-
lesion leprosy (SLL) where protection only 
lasted 2 years. These findings indicate that 
the SDR treatment is only effective when 
the patient has a low load 
mycobacterial(10). 
While on TB chemoprophylaxis is a 
therapy for the prevention of infection with 
Mycobacterium tuberculosis or to avoid the 
development of disease in individuals 
already infected with Mycobacterium 
tuberculosis. Isoniazid therapy is most 
commonly used, however, the use of 
rifampicin and pyrazinamide also been 
carried out. Investigation of contacts in 
giving chemoprophylaxis is also very 
important (21). In a research found that 
there are effects of isoniazid therapy on 
cytokine responses reflecting 
mycobacterial burden reduction in close 
contact, and therefore should be taken as a 
positive response to the prevention and 
treatment(19), In giving chemoprophylaxis 
isoniazid (INH) is effective given to groups 
ILTB (infection latent tuberculosis), 
children's age <5 years close contact with 
TB patients (infected individual 
secondary), and in HIV/AIDS prevention, 
for people living with HIV/AIDS-
susceptible tuberculosis (8). As conclusion, 
herewith in table 1 the comparison for using 
immunoprophylaxis and chemoprophylaxis 
in order to prevent tuberculosis and leprosy 
infection. 
Tabel 1 : Comparison The Use of Immunoprophylaxis versus Chemoprophylaxis in 
Tuberculosis and Leprosy Prevention  
Type of Preventive Diseases % of protection  
Immunophrophylaxis 
(BCG) 
Pulmonary tuberculosis 2-83% 
Extra pulmonary tuberculosis 54-78% 
Leprosy 26-41% 
Chemophrophylaxis 
(Single Dose Rifampicin) 
Tuberculosis unknown 
Leprosy 
60% (within 5 years, and 
need to be repeated if still be 
exposed 
 
Future work 
Preventing in TB and Leprosy is an 
important strategy to stop the diseases 
transmission. Immunoprophylaxis is one of 
strategy, however, the prevention rate 
remains less than 80%. Also with 
chemoprophylaxis, Isoniazid and 
rifampicin in TB gave low efficacy, also 
with SDR in Leprosy, around 60%. As 
shown by the combination treatment 
strategies, provision and administration of 
chemoprophylaxis and immunoprophylaxis 
suggested as an active control strategy in 
reducing the incidence of leprosy. Some 
studies suggest that BCG produces 
relatively common protection to be used as 
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a preventive vaccination leprosy disease, 
especially in the contact. Because there is 
no great benefit as leprosy disease 
prevention WHO does not recommend 
revaccination BCG as prevention of disease 
leprosy (9). Giving a single dose of 
rifampicin and BCG to  contact without 
symptoms, can prevent many potential 
cases and reduce ongoing transmission (5). 
In the future, doing research in 
preventing TB and Leprosy remains high 
priority, whether, find more effective 
vaccines for both TB and Leprosy nor 
provide better combination of 
chemoprophylaxis. 
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